By the numbers
0.0M
Medical communitymembers
0K
Curated contentpieces
0M+
Monthlypageviews
By the numbers
0.0M
Medical communitymembers
0K
Curated contentpieces
0M+
Monthlypageviews
TribeMD
Eventos
Notícias em alta
SGO 2026Apr 14, 2026
8 min read
Mirvetuximab Advances to Platinum-Sensitive Ovarian Cancer: ORR of 62.7% in Phase 2 Study
IMGN853-0420 at SGO 2026: mirvetuximab soravtansine + carboplatin shows robust response in FRα-positive PSOC — expanding potential across the ovarian cancer treatment continuum.Approved in 2022 for FRα-positive platinum-resistant ovarian cancer, mirvetuximab soravtansine has already demonstrated superiority over chemotherapy in the MIRASOL study — now with confirmed OS after 30 months of follow-up. But the clinical ambition for the anti-FRα ADC went further: what ha
SGO 2026Apr 14, 2026
8 min read
CDK46 in Endometrial Cancer: Abemaciclib + Letrozole Delivers Disease Control Without Chemotherapy
GOG-3039 phase 2 meets primary endpoint: 6-month PFS of 56.9% — and 71.4% in chemo-naïve patients. A new hormonal era for endometrioid carcinoma.Hormone receptor-positive breast cancer inaugurated the CDK4/6 inhibitor era — palbociclib, ribociclib, and abemaciclib were incorporated into the standard of care and transformed outcomes for patients with metastatic disease. The question gynecologic oncology had been asking for years was inevitable: does this same paradig
SGO 2026Apr 14, 2026
For the first time: Immunotherapy changes survival in Platinum-Resistant ovarian cancer
KEYNOTE-B96 confirms OS benefit with pembrolizumab + weekly paclitaxel ± bevacizumab — FDA approved in February 2026.For decades, oncology tried — and repeatedly failed — to incorporate immunotherapy into the ovarian cancer treatment arsenal. JAVELIN Ovarian 200 and AGO-OVAR 2.29 were negative. Skepticism toward checkpoint inhibitors in this setting had almost reached consensus. KEYNOTE-B96 arrived to dismantle that consensus.The ENGOT-ov65/KEYNOTE
OncologyApr 9, 2026
8 min read
Adjuvant chemotherapy improves survival in older women with triple-negative breast cancer, study finds
A recent population-based study has provided relevant evidence for a common question in oncology practice: do older women with nonmetastatic triple-negative breast cancer benefit from adjuvant chemotherapy? According to the published data, the answer appears to be yes. In an analysis of more than 5,700 patients aged 70 years or older, adjuvant chemotherapy was associated with a significant improvement in both breast cancer–specific survival and overall survival. The study used data fro
